Nature Communications (Jul 2020)
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
- Kayoko Hosaka,
- Yunlong Yang,
- Takahiro Seki,
- Qiqiao Du,
- Xu Jing,
- Xingkang He,
- Jieyu Wu,
- Yin Zhang,
- Hiromasa Morikawa,
- Masaki Nakamura,
- Martin Scherzer,
- Xiaoting Sun,
- Yuanfu Xu,
- Tao Cheng,
- Xuri Li,
- Xialin Liu,
- Qi Li,
- Yizhi Liu,
- An Hong,
- Yuguo Chen,
- Yihai Cao
Affiliations
- Kayoko Hosaka
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Yunlong Yang
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Takahiro Seki
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Qiqiao Du
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Xu Jing
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Xingkang He
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Jieyu Wu
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Yin Zhang
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Hiromasa Morikawa
- Unit of Computational Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institute
- Masaki Nakamura
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Martin Scherzer
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Xiaoting Sun
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Yuanfu Xu
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Tao Cheng
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Xuri Li
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
- Xialin Liu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
- Qi Li
- Department of Medical Oncology and Cancer Institute, Shuguang Hospital Shanghai University of Traditional Chinese Medicine
- Yizhi Liu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
- An Hong
- Department of Cell Biology, Institute of Biomedicine, Jinan University
- Yuguo Chen
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Yihai Cao
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- DOI
- https://doi.org/10.1038/s41467-020-17525-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Anti-VEGF therapy has many limitations that might be resolved by using combination treatment approaches. Here, the authors demonstrate that the dual-targeting of VEGF and PDGF is required for targeting resistant FGF2+ tumors which depend on the recruitment of pericytes on tumor microvessels.
